Fundraising Fox
🦊/People
Sign in

Detlev Biniszkiewicz

Investor

Managing Director at MPM BioImpact · Board director at iTeos Therapeutics · Board director at Rekindle Therapeutics · Board director at NextPoint Therapeutics

Boston, Massachusetts

Find your path to Detlev

563 people in our graph share verified history with Detlev — schools, employers, funds. One of them is your warm intro.

Wesley ChanunlockedDetlev: together at Massachusetts Institute of Technology (1996–2001)
×10Detlev: together at Massachusetts Institute of Technology
Detlev: together at Boston Consulting Group

About

Managing Director and serial entrepreneur with deep expertise in oncology and immuno-oncology. Recently served as CEO of portfolio company NextPoint Therapeutics and currently chairs its Board. Previously President and CEO of Surface Oncology and held strategic roles at AstraZeneca and Novartis.

Board director at iTeos Therapeutics

Intro paths

→

In turn, Detlev can intro founders to iTeos Therapeutics's investors below.

iTeos Therapeutics's investors · 10

6 Dimensions CapitalGrand Cayman · since 2020Curative VenturesDallas · since 2020Fund+Leuven · $5.5M – $16.5M checks · since 2020HBM PartnersZug · $5M – $50M checks · since 2020InvusNew York · since 2020Janus Henderson InvestorsLondon · since 2020MPM BioImpactBoston · $1M – $15M checks · since 2020RA CapitalBoston · since 2020RTW Investments L.P.New York · since 2020VIVES PartnersWavre · $108K – $7.6M checks · since 2020

Co-founders at iTeos Therapeutics

MDMichel Detheux
Michel DetheuxExecutive Officer, Director

Board director at Rekindle Therapeutics

Intro paths

→

In turn, Detlev can intro founders to Rekindle Therapeutics's investors below.

Rekindle Therapeutics's investors · 1

MPM BioImpactBoston · $1M – $15M checks · since 2018

Board director at NextPoint Therapeutics

Intro paths

→

In turn, Detlev can intro founders to NextPoint Therapeutics's investors below.

NextPoint Therapeutics's investors · 7

Catalio Capital ManagementNew York · since 2024Catalio Capital Management, LPNew YorkInvusNew York · since 2024Leaps by BayerLeverkusen · since 2024MPM BioImpactBoston · $1M – $15M checks · since 2024Sanofi VenturesCambridge · $5M checks · since 2024Sixty Degree CapitalNorth York · since 2024

Co-founders at NextPoint Therapeutics

GFGordon Freeman
Gordon FreemanScientific Founder
XZXingXing Zang
XingXing ZangScientific Founder

Experience

  1. MPM BioImpactManaging Director/Investment Partner - MPM Innovation Fundcurrent2020 — present
  2. MPM BioImpactFounder, Chairman, & Former CEO - NextPoint Therapeutics2018 — 2024
  3. MPM BioImpactFounder, President & CEO - Sieben Therapeutics2020 — 2023
  4. MPM BioImpactExecutive Partner & Serial Entrepreneur2018 — 2022
  5. NextPoint Therapeutics, Inc.Founder, Chairman of the Boardcurrent2022 — presentGreater Boston
  6. NextPoint Therapeutics, Inc.Founder, CEO, and President2018 — 2023Greater Boston
  7. Montis BiosciencesBoard of Directors - Independent2019 — 2024
  8. iTeos TherapeuticsBoard of Directors2019 — 2023Greater Boston
  9. 1K OncologyFounder/CEO2020 — 2022Greater Boston
  10. Maverick TherapeuticsBoard of Directors2018 — 2021San Francisco Bay Area
  11. Tilos TherapeuticsBoard of Directors - Independent2018 — 2020Greater Boston Area
  12. Surface Oncology Inc.Board Of Directors2015 — 2018
  13. Surface Oncology Inc.President & CEO2015 — 2017Greater Boston Area
  14. AstraZenecaVice President, Oncology - Strategy, External Science & Licensing2011 — 2015Greater Boston Area
  15. NovartisGlobal Head - Portfolio Management & Analysis2008 — 2011Greater Boston Area
  16. NovartisHead - Strategic Projects and Planning2007 — 2008Greater Boston Area
  17. Boston Consulting GroupPrincipal2001 — 2007Greater Boston Area

Skills & more

Biotechnology41Drug Discovery34Lifesciences12Oncology31Biopharmaceuticals12Technology Transfer6Clinical Development12Drug Development13Business Strategy1Clinical Research1Commercialization4Cross-functional Team Leadership3
+11 moreClinical TrialsCancerCell BiologyBiomarkersGeneticsGenomicsImmunologyLife SciencesStrategyPharmaceutical IndustryLeadership

From Detlev's professional profile.

Investments

Sources: SEC Form D filings · curated public sources.

Colleagues at MPM BioImpact

Alan Kelly
Director at MPM BioImpact
Andrew Scharenberg
Entrepreneur Partner at MPM BioImpact
Ansbert Gadicke, M.D.
Chairman at MPM BioImpact
Ansbert K. Gadicke
Managing Partner at MPM BioImpact
Aparna Parikh
Entrepreneur Partner at MPM BioImpact
Bard Geesaman
Managing Partner at MPM Capital
Binsen Li
Principal at MPM BioImpact
Brendan Furey
Chief Compliance Officer at MPM BioImpact

Network4

Ansbert K. Gadicke
Managing Partner at MPM BioImpact
Bard Geesaman
Managing Partner at MPM Capital
Briggs Morrison
Entrepreneur Partner at MPM BioImpact
Dan Hicklin
Managing Partner at MPM Capital

Investors connected to Detlev in public investor directories — a warm-intro map.

Frequently asked questions

Who is Detlev Biniszkiewicz?
Managing Director and serial entrepreneur with deep expertise in oncology and immuno-oncology. Recently served as CEO of portfolio company NextPoint Therapeutics and currently chairs its Board. Previously President and CEO of Surface Oncology and held strategic roles at AstraZeneca and Novartis.
Where does Detlev Biniszkiewicz work?
Detlev Biniszkiewicz is Managing Director at MPM BioImpact and Board director at iTeos Therapeutics and Board director at Rekindle Therapeutics and Board director at NextPoint Therapeutics.
What boards does Detlev Biniszkiewicz sit on?
Detlev Biniszkiewicz holds tracked board seats at NextPoint Therapeutics.
What companies has Detlev Biniszkiewicz invested in?
Investments tracked here include Deka Biosciences, NextPoint Therapeutics.
Where did Detlev Biniszkiewicz go to school?
Detlev Biniszkiewicz studied at Massachusetts Institute of Technology (Ph.D. and Post-Doc Research, Genetics).

Founder mafias

Same school

Shared employers